An expert consensus on the medical management of uterine fibroids and complementing surgical management with focus on low dose mifepristone

Dr. Alka Kriplani, Dr. Basab Mukherjee, Dr. Sadhana Gupta, Dr. Indu Singh, Dr. Sushma Pandey, Dr. Anita Singh, Dr. Mukesh Chandra, Dr. Girija Wagh, Dr. Suruchi Desai, Dr. Arun Madhab Baruah, Dr. Sherley Mathen and Dr. Queen Aditya

DOI: https://doi.org/10.33545/gynae.2024.v8.i3a.1452

Abstract

Objectives: The aim of this consensus guideline is to provide clinicians with an understanding of the clinical significance of uterine fibroids and the best evidence available on treatment modalities with a focus on low dose mifepristone as an option for patients who need symptom relief preoperatively or postoperatively.

Methods: The areas of clinical practice considered in formulating this consensus statement shared by gynecologists during the meeting were organized into four key themes, namely screening and diagnosis of fibroids, medical management of fibroids, role of low dose mifepristone in the medical management of fibroids, and complimenting surgical management of fibroids with low dose mifepristone.

Results: Medical and surgical procedures were analyzed in the therapy of uterine fibroids. Novel medical approaches with low dose mifepristone (25 mg) were explored and found to establish an effective new therapy. Mifepristone may be used as a pre-operative adjunct to reduce the size of fibroids. Post-operative use of mifepristone can be typically initiated at a low dose of 25 mg. Ultrasound examinations were suggested to monitor the uterine fibroids. Mifepristone is safe even when used for a prolonged duration. Mifepristone has low cumulative incidence of fibroid recurrence after surgery, and provides faster recovery of reproductive function.

Conclusion: Implementation of this consensus statement should optimize the decision-making process of women and their physician in assessment of treatment for uterine fibroids, having considered the disease process and available treatment options, and evaluated the risks and anticipated benefits. New options now exist, with mifepristone, a progesterone receptor antagonist proven to treat fibroid symptoms effectively. These recommendations can improve the quality of care for women with uterine fibroids utilizing the best available evidence and best clinical practices.

Keywords: Uterine fibroids, mifepristone, ultrasound, myomectomy, hysterectomy

Introduction

Uterine fibroids are a prevalent gynecological concern affecting a substantial portion of women during their reproductive years [1-4]. A recent meeting of gynecologists convened to discuss the management of uterine fibroids (UF) and explored the potential role of mifepristone (MFP) in addressing this complex condition.

Methods

In this review article, we delved into the insights and perspectives shared by gynecologists during the meeting, and organized them into four key thematic areas, namely screening and diagnosis of fibroids, medical management of fibroids, role of low dose MFP in the medical management of fibroids, and complimenting surgical management of fibroids with low dose MFP.

Results

Screening and Diagnosis of Fibroids: Assessment of uterine fibroids and selection of treatment options are guided by imaging techniques such as ultrasound.
Ultrasonography as the Preferred Screening Tool
Ultrasonography (USG) should be the preferred initial investigation for asymptomatic women with suspected uterine fibroids. The accessibility and non-invasiveness of USG make it an indispensable diagnostic tool for assessing uterine fibroids. It’s ability to provide detailed information on fibroid characteristics cannot be overstated [5-7]. Regular USG screenings, with intervals of at least 3 months between tests to monitor any changes in fibroid size and location is important. The location and size of uterine fibroids are critical. Thorough evaluation is needed to guide treatment decisions effectively. Many fibroids may be discovered incidentally during unrelated medical examinations [8-9]. Such findings should prompt further evaluation, given the potential impact on a woman’s reproductive health.

Recommendations for yearly screening or USG in high-risk patients; assessing the volume, not just the size, of fibroids is essential. Preconception checkups should include an assessment for uterine fibroids to facilitate informed reproductive choices.

Patient Counseling and Public Awareness: There is a general lack of awareness of fibroids and their potential health impact among women [9-10]. 95.73% lack knowledge about uterine fibroids. 92.68% have a dissatisfactory perception on fibroids. It is important to have patient counseling and increased public awareness regarding uterine fibroids. Early detection and education can empower women to make well-informed decisions about their health. The gynecologists shared key insights regarding the screening and diagnosis of uterine fibroids in asymptomatic women. The consensus on the importance of ultrasonography and the critical role of patient counseling set the stage for further exploration of uterine fibroids management and the potential integration of mifepristone.

Medical Management of Uterine Fibroids
Patient-focused fibroid management is guided by medical history, physical examination, imaging, and results of blood tests. If patients begin to experience symptoms and require treatment, a definite fibroid management plan can be developed.

Table 1: Assessment Recommendations for Practice

<table>
<thead>
<tr>
<th>Clinical Recommendations</th>
<th>Use ultrasonography as the initial investigation for asymptomatic women with suspected uterine fibroids</th>
</tr>
</thead>
<tbody>
<tr>
<td>Conduct regular ultrasound screenings with at least 3-month intervals to monitor changes in fibroid size and location</td>
<td></td>
</tr>
<tr>
<td>Consider yearly screenings or ultrason in high-risk patients</td>
<td></td>
</tr>
<tr>
<td>Assess both the volume and size of fibroids for a comprehensive evaluation</td>
<td></td>
</tr>
<tr>
<td>Include uterine fibroid assessment in preconception checkups to support informed reproductive choices</td>
<td></td>
</tr>
<tr>
<td>Prioritize patient counseling and raise public awareness about uterine fibroids</td>
<td></td>
</tr>
</tbody>
</table>

Table 2: Summary of Recommended Treatment Options for Uterine Fibroids

<table>
<thead>
<tr>
<th>Recommended Therapies</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lifestyle changes, dietary modifications, and exercise are important to manage fibroid-related symptoms</td>
</tr>
<tr>
<td>Mifepristone should be preferred over GnRH agonists for its ability to immediately stop bleeding and lower the risk of heavy bleeding during the first cycle</td>
</tr>
<tr>
<td>Mifepristone carries very low risk of pregnancy compared to GnRH agonists</td>
</tr>
<tr>
<td>Surgery should be considered for women above 40 years of age</td>
</tr>
</tbody>
</table>

Treatment options for uterine fibroids include observation, medical intervention, surgical procedures or a combination.8 Treatment of women with uterine fibroids should be individualized to the size and location of the fibroid, the patient’s age, symptoms, desire to maintain fertility, and access to treatment; and the physician’s experience.

Table 3: Tailoring Treatment to Patient Characteristics [6]

<table>
<thead>
<tr>
<th>Patient characteristics</th>
<th>(Uterine artery embolization has to be done at certified centre)</th>
<th>Treatment options</th>
</tr>
</thead>
<tbody>
<tr>
<td>Asymptomatic women</td>
<td></td>
<td>Observation</td>
</tr>
<tr>
<td>Symptomatic women who desire fertility preservation</td>
<td></td>
<td>Non-surgical treatment or myomectomy</td>
</tr>
<tr>
<td>Symptomatic women who do not desire future fertility but wish to preserve the uterus</td>
<td></td>
<td>Non-surgical treatment or myomectomy, myolysis, or uterine artery embolization</td>
</tr>
<tr>
<td>Women who desire fertility preservation and have had a pregnancy complicated by uterine fibroid tumors</td>
<td></td>
<td>Myomectomy</td>
</tr>
<tr>
<td>Infertile women with distortion of uterine cavity</td>
<td></td>
<td>Myomectomy</td>
</tr>
<tr>
<td>Women with severe symptoms who desire definitive treatment</td>
<td></td>
<td>Hysterectomy</td>
</tr>
</tbody>
</table>

Table 4: Effective use of Mifepristone in Fibroids

<table>
<thead>
<tr>
<th>Several advantages of mifepristone are as follows [7,11]</th>
</tr>
</thead>
<tbody>
<tr>
<td>Up to 50% reduction in uterine/fibroid volume</td>
</tr>
<tr>
<td>Amenorrhea in up to 70% of women</td>
</tr>
<tr>
<td>Oral administration</td>
</tr>
<tr>
<td>Minimal side effects</td>
</tr>
<tr>
<td>Less expensive than GnRH analogues</td>
</tr>
<tr>
<td>Very low risk of bleeding</td>
</tr>
<tr>
<td>80-85% success rate</td>
</tr>
<tr>
<td>Drug of choice in infertility and type 3 myomas</td>
</tr>
<tr>
<td>Use for acute abnormal uterine bleeding</td>
</tr>
</tbody>
</table>
Tranexamic acid reduces heavy menstrual bleeding but it has no effect on fibroid size.12 Moreover, caution must be exercised with its use, as indiscriminate use can lead to very high platelet counts. The utilization of low-dose mifepristone (25 mg) in the medical management of uterine fibroids is a subject of growing interest and debate.

**Table 5: Role of Low-Dose 25 mg Mifepristone in Medical Management of Uterine Fibroids**

<table>
<thead>
<tr>
<th>Clinical Recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treatment regimens for mifepristone in uterine fibroids may include 25 mg for three months followed by a USG evaluation, or 25 mg for three months followed by 10 mg for an additional six months.</td>
</tr>
<tr>
<td>Mifepristone can be safely used for 6-9 months; with liver function tests recommended three-monthly.</td>
</tr>
</tbody>
</table>

**Clinical Evidence on the Use of Low-Dose Mifepristone (25 mg)**

Multiple studies were presented to support the efficacy of mifepristone in fibroid management, with a particular focus on its use in low-dose regimens. Various studies demonstrated benefits on reduction of myoma volume and size when 25 mg mifepristone was given for 3 to 6 months.13-16

**Safety of Prolonged Mifepristone Use**17: Mifepristone is safe even when used for a prolonged duration. No evidence of hyperplasia or atypia in the endometrium has been reported, supporting its use over extended period of 6 months in the management of uterine fibroids.

**Complimenting surgical management of Fibroids with Low Dose Mifepristone**

Mifepristone may directly decrease the progesterone receptor (PR) in the myometrium.

**Medical therapy complements surgical therapy**7,18-22

- As a pre-operative adjunct.
- To reduce the size of fibroids.
- To control bleeding.
- To improve blood hemoglobin levels.
- To make surgery easier.
- As a post-operative adjunct.
- To relieve signs and symptoms.
- To prevent recurrence of fibroids after uterine conserving procedures.

Several advantages of mifepristone make it a compelling alternative to other treatments, particularly GnRH agonists which includes. Mifepristone has low cumulative incidence of fibroid recurrence after surgery, and provides faster recovery of reproductive function.

**Conclusions Future Directions**

The experts also discussed potential future directions for mifepristone use. One notable prospect is it’s application in the management of acute abnormal uterine bleeding (AUB), potentially involving high-dose regimens as a starting point. This signifies an ongoing exploration of mifepristone’s role in the ever-evolving landscape of uterine fibroid management.

**Conflict of Interest:** Not available.

**Financial Support:** Not available.

**References**


Dr. Alka Kriplani
Department of Obstetrics and Gynecology, Paras Hospital, Gurugram, Haryana, India

Dr. Basab Mukherjee
Aashirbad Clinic, Salt Lake City, Kolkata, West Bengal, India

Dr. Sadhana Gupta
Jeevan Jyoti Hospital & Medical Research Center, Bobina Road, South - Jatepur, Gorakhpur, Uttar Pradesh, India

Dr. Indu Singh
Surya Super Speciality Hospital Dayal Enclave, Uttar Pradesh, India

Dr. Sushma Pandey
Pandey Nursing Home. K. Bag. Opp. Sri Ram Hospital, Patna, Bihar, India

Dr. Anita Singh
Jan Chikitsa Hospital, Mithapur Road, Mithapur, Patna, Bihar, India

Dr. Mukesh Chandra
Chandra Clinic, Church Road, Civil Line, Agra, Uttar Pradesh, India

Dr. Girija Wagh
Primrose Wellness & Care, Kothrud, Pune, Maharashtra, India

Dr. Suruchi Desai
Consulting, Department of Obstetrics and Gynecology, Nanavati Max Super Speciality Hospital, Mumbai, Maharashtra, India

Dr. Arun Madhab Baruah
Apollo Fertility, Reliance Trends building, GS Rd, Ananda Nagar, Christian Basti, Guwahati, Assam, India

Dr. Sherley Mathen
Aster Medcity, Cochin, Kerala, India

Dr. Queen Aditya
Nova Medical Services, Behala, Kolkata, West Bengal, India

How to Cite This Article

Creative Commons (CC) License
This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.